

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
30 March 2024 :: Issue 744
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



Dengue

[PAHO calls for collective action in response to record increase in dengue cases in the Americas](#)

Washington, DC, March 28, 2024 (PAHO)- The Pan American Health Organization (PAHO) today warned about the surge in dengue cases in the Americas. **As of March 26, 2024, over 3.5 million cases and more than 1,000 deaths have been reported in the region.**

"This is cause for concern, as it represents three times more cases than those reported for the same period in 2023, a record year with more than 4.5 million cases reported in the region," PAHO Director Jarbas Barbosa said during a press briefing.

While dengue is on the rise throughout Latin America and the Caribbean, the hardest-hit countries are **Brazil (83%), Paraguay (5.3%), and Argentina (3.7%), which account for 92% of cases and 87% of deaths.** This increase is attributed to the higher transmission season in the southern hemisphere, when the *Aedes aegypti* mosquito vector of dengue thrives due to warm and rainy weather.

However, Dr. Barbosa cautioned that "we are also seeing an uptick in cases in countries such as Barbados, Costa Rica, Guadeloupe, Guatemala, Martinique and Mexico, where transmission is usually higher in the second half of the year."

The PAHO Director also noted the presence of the mosquito vector and cases in new geographical areas, raising concerns that some countries may not be prepared to face an increase in transmission...

The presence of all four dengue serotypes in the region increases the risk of epidemics and severe forms of the disease. The simultaneous circulation of two or more dengue serotypes has been observed in 21 countries and territories of the Americas.

Dr. Barbosa emphasized the importance of taking prompt action to prevent and control dengue transmission and avoid deaths, noting that "despite the record increase in cases in 2023, the dengue case fatality rate in the region remained below 0.05%." This, he noted, "is very encouraging, considering the spikes in cases we have seen since then."...

The PAHO Director called for action, urging intensified efforts to eliminate mosquito breeding sites and protect against mosquito bites, increase preparedness in health services for early diagnosis and timely clinical management, and continuous work to educate the population about dengue symptoms and when to seek prompt medical attention.

"Facing the dengue problem is a task for all sectors of society," Dr. Barbosa said, calling for "community engagement in order to succeed in our efforts."



Pandemic Accord

[WHO Member States agree to resume negotiations aimed at finalizing the world's first pandemic agreement](#)

28 March 2024 News release

WHO Member States agreed to resume negotiations aimed at finalizing a pandemic agreement during 29 April to 10 May. The decision came at today's end of two weeks of intensive country-led discussions on critical subjects aimed at making all countries of the world better prepared for, and able to effectively and equitably respond to, future pandemics.

This [ninth meeting](#) of the [Intergovernmental Negotiating Body](#) (INB9) started on 18 March and ended today. Government negotiators discussed all articles from the [draft agreement](#), including adequate financing for pandemic preparedness, equitable access to medical countermeasures needed during pandemics and health workforce strengthening.

"Our Member States are fully aware of how important the pandemic agreement is for protecting future generations from the suffering we endured through the COVID-19 pandemic," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "I thank them for their clear commitment to finding common ground and finalizing this historic agreement in time for the World Health Assembly."

Next month's resumption of INB9 will be a critical milestone ahead of the Seventy-seventh World Health Assembly, starting 27 May 2024, at which Member States are scheduled to consider the proposed text of the world's first pandemic agreement for adoption.

Dr Precious Matsoso, Co-Chair of the INB Bureau, said: "There is clear recognition from governments that **the goal of a pandemic agreement is to prepare the world for preventing and responding to future pandemics, built on consensus, solidarity and equity**. These goals must remain our North Star as we move toward the finalization of this historic, pressing commitment for the world. We know that if we fail, we will be failing humanity, including all those who suffered from COVID-19, and those at risk of future pandemics."...

In [December 2021](#), the World Health Assembly met in a Special Session, the second-ever since WHO's founding in 1948, and decided to establish the INB to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness and response. The process has involved participation of other United Nations system bodies, non-state actors, other relevant stakeholders, and the public.



[Faith-based partners voice support for pandemic accord](#)

28 March 2024 WHO Departmental news

...WHO convenes the [Faith Network for emergency preparedness and response](#) with the aim of increasing access to accurate and relevant information. The network strives to foster a community of collaborative sharing on topics related to health emergency preparedness and response, as well as the intersection between faith and public health. WHO Faith Network was formalized in early 2022 with over 50 partners representing a diversity of faiths including service providers, faith leaders, faith-based organizations (FBOs), and academic institutions.

This statement was developed and circulated by members* of the WHO Faith Network for emergency preparedness and response, not by WHO. The statement can be accessed at partners' websites including [World Vision International](#)...

[World of Work stakeholders voice support for the pandemic accord, highlighting workers' rights and needs during pandemics](#)

27 March 2024 WHO Departmental news

...stakeholders of WHO Health in World of Work Network (H-WoW) have [released a statement](#) in support of progress on developing the pandemic accord and for amendments proposed by the [International Labour Organization](#)...

.....

[Rifts over equity imperil WHO's pandemic treaty](#)

Science, 21 Mar 2024: 1276-1277

BY Jon Cohen

As deadline nears, negotiations continue over sharing pathogen sequences and vaccine doses

.....

.....

CoViNet

[WHO launches CoViNet: a global network for coronaviruses](#)

27 March 2024 News release

WHO has launched a new network for coronaviruses, CoViNet, to facilitate and coordinate global expertise and capacities for early and accurate detection, monitoring and assessment of SARS-CoV-2, MERS-CoV and novel coronaviruses of public health importance.

CoViNet expands on the WHO COVID-19 reference laboratory network established during the early days of the pandemic. Initially, the lab network was focused on SARS-CoV-2, the virus that causes COVID-19, but **will now address a broader range of coronaviruses, including MERS-CoV and potential new coronaviruses**. CoViNet is a network of global laboratories with expertise in human, animal and environmental coronavirus surveillance.

The network currently includes 36 laboratories from 21 countries in all 6 WHO regions.

Representatives of the laboratories met in Geneva on 26 – 27 March to finalize an action plan for 2024-2025 so that WHO Member States are better equipped for early detection, risk assessment, and response to coronavirus-related health challenges.

The CoViNet meeting brings together global experts in human, animal, and environmental health, embracing a comprehensive One Health approach to monitor and assess coronavirus evolution and spread. The collaboration underscores the importance of enhanced surveillance, laboratory capacity, sequencing, and data integration to inform WHO policies and support decision-making...

.....

.....

Smallpox Countermeasures

[Action Needed to Improve U.S. Smallpox Readiness and Diagnostics, Vaccines, and Therapeutics, Says New Report](#)

News Release / March 26, 2024

WASHINGTON — A [new report](#) from the National Academies of Sciences, Engineering, and Medicine says that action is needed to enhance U.S. readiness for smallpox and related diseases, as well as to improve diagnostics, vaccines, and therapeutics that could be used in case of an outbreak. The COVID-19 pandemic revealed weaknesses in the ability of U.S. public health and health care systems to adapt and respond to an unfamiliar pathogen, as did challenges during the recent mpox outbreak to rapidly making diagnostics, vaccines, and therapeutics available at scale.

The development of better diagnostics, vaccines, and therapeutics — also called medical countermeasures — would improve the nation’s ability to respond to a smallpox outbreak or attack using the virus, the report says. It also calls for strengthening the systems and policies that would allow public health and health care systems to act quickly and effectively, such as those that could support rapid distribution of a vaccine.

The report says U.S. population changes and advancements in gene editing and synthesis technologies have drastically altered the potential for a smallpox outbreak or attack in recent years. It is now possible to engineer variola virus, the virus that causes smallpox, raising the possibility of accidental or intentional release. Furthermore, illnesses related to smallpox such as mpox, Alaskapox, and cowpox are increasingly found in humans, presenting the need for medical countermeasures that can detect, treat, and prevent these diseases...

Smallpox Diagnostics, Vaccines, and Therapeutics

The committee that wrote the report examined the state of medical countermeasures that have been developed and stockpiled in the U.S. Strategic National Stockpile to identify, prevent, and treat smallpox. Despite research done in recent decades and the fact that more smallpox medical countermeasures are available now than before the disease was eradicated, the nation’s ability to respond to a smallpox event could be strengthened.

The report says:

- **Diagnostic tests** are needed that can more accurately detect smallpox and related viruses, identify potential cases at earlier stages of disease, assess prior exposure or immunity to smallpox, be used across biosafety levels and in field settings, support disease surveillance, and enhance equitable access to testing than those available today.
- **Vaccines** that are safer, can be used across different populations, and are available as a single dose would support a faster and more effective response to a smallpox outbreak. Developing new smallpox vaccines that use a multi-vaccine platform — which use common vaccine vectors, manufacturing ingredients, and processes — would improve the capacity for rapid production and reduce the need for stockpiling.
- **Therapeutic options** that are safer and more diversified — such as antivirals with different and diverse targets, mechanisms of action, and routes of administration, or treatments based on novel technologies and platforms — would be advantageous supplements to existing therapeutics.

“The gaps in our ability to respond to a new infectious disease were revealed by the COVID-19 pandemic and recent mpox outbreak,” said committee chair Larry Gostin, distinguished university professor and director of the WHO Organizing Collaborating Center on National and Global Health Law at Georgetown University. **“It is vital to prioritize research into the development of safer and more effective smallpox diagnostics, vaccines, and therapeutics, make**

judicious choices in stockpiling, and have modern, well-practiced, and adaptable plans for responding in the event of a smallpox outbreak.”

“The eradication of smallpox is one of the most significant accomplishments of medicine and public health, ending an ancient scourge of humanity,” said Victor J. Dzau, president of the National Academy of Medicine. “We have to protect against the reemergence of this disease by maintaining and strengthening effective and safe medical countermeasures.”...

.....

[Future State of Smallpox Medical Countermeasures](#)

NASEM, 2024 161 pages

PDF: <https://nap.nationalacademies.org/download/27652>

Contributor(s): National Academies of Sciences, Engineering, and Medicine; [Health and Medicine Division](#); [Division of Earth and Life Studies](#); [Board on Health Sciences Policy](#); [Board on Global Health](#); [Board on Life Sciences](#); [Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures](#); Lawrence O. Gostin, Lisa Brown, Shalini Singaravelu, and Matthew Masiello, Editors

At the request of the Administration for Strategic Preparedness and Response, the National Academies convened a committee to examine lessons learned from the COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the state of smallpox research, development, and stockpiling of medical countermeasures (MCM). In the resulting report, the committee presents findings and conclusions that may inform U.S. Government investment decisions in smallpox MCM readiness, as well as the official U.S. position on the disposition of live viral collections at future World Health Assembly meetings.

.....
.....
.....

Polio – PHEIC

[Polio this week as of 27 Mar 2024 - GPEI](#)

:: On 27 March 2014, WHO’s South-East Asia Region (SEARO) was certified wild polio free – a massive undertaking in a region that is home to one-quarter of the world’s population. Now, a decade later, all 11 countries in the region are still free of the virus, thanks to continued commitments to vaccination and disease surveillance.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: 10 WPV1-positive environmental samples
- Pakistan: 15 WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Burkina Faso: one cVDPV2 case
- Chad: one cVDPV2-positive environmental sample
- Côte d’Ivoire: two cVDPV2-positive environmental samples
- Liberia: one cVDPV2-positive environmental sample
- Nigeria: five cVDPV2-positive environmental samples
- South Sudan: two cVDPV2 cases

.....
.....

Contents [click to move among sections]

[:: Milestones, Perspectives](#)

[:: WHO](#)

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 30 Mar 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

30 March 2024 Departmental news

[**2023: outbreaks of swine influenza**](#)

30 March 2024 Departmental news

[**2023: outbreaks of avian influenza**](#)

30 March 2024 Departmental news

[**Influenza Health Worker Vaccination Programmes: Platforms for Pandemic Preparedness**](#)

30 March 2024 Departmental news

[**Updated public health resource pack for countries experiencing outbreaks of influenza in animals published!**](#)

30 March 2024 Departmental news

[**Promoting a risk-based approach for the regulatory oversight of vaccines used in pandemics**](#)

30 March 2024 Departmental news

[**PAHO drives evidence-generation on the burden of influenza through strategic research initiatives**](#)

29 March 2024 Departmental news

[**WHO publishes new guidelines on hepatitis B**](#)

28 March 2024 News release

[**WHO Member States agree to resume negotiations aimed at finalizing the world's first pandemic agreement**](#)

28 March 2024 Departmental news

[**Faith-based partners voice support for pandemic accord**](#)

28 March 2024 Departmental news

[**Timor-Leste's National Influenza Centre achieves recognition as part of the WHO Global Influenza Surveillance and Response System**](#)

27 March 2024 Departmental news

[**World of Work stakeholders voice support for the pandemic accord, highlighting workers' rights and needs during pandemics**](#)

27 March 2024 News release

[WHO launches CoViNet: a global network for coronaviruses](#)

27 March 2024 Departmental news

[WHO launches guidance on conducting reviews of tuberculosis programmes](#)

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 27 March 2024

[African island states take fresh step towards joint medicines procurement](#)

:: 24 March 2024

[Combined HIV-TB testing, care curbing infection and mortality in Niger](#)

:: 23 March 2024

[Intensifying new initiatives for TB case-finding in Nigeria](#)

:: 23 March 2024

[Rate of TB diagnosis, treatment in Africa increasing](#)

WHO Region of the Americas PAHO

:: 28 Mar 2024

[PAHO calls for collective action in response to record increase in dengue cases in the Americas](#)

Washington, DC, March 28, 2024 (PAHO)- The Pan American Health Organization (PAHO) today warned about the surge in dengue cases in the Americas. As of March 26, 2024, over 3.5 million cases and more than 1,000 deaths have been reported in the region."This is cause for concern, as it represents three times more cases than those...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: **[Yemen conflict enters 10th year with over 17 million people in need of health aid](#)**

25 March 2024

WHO Western Pacific Region

No new digest content identified.

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

Disease Outbreak News (DONs)

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
No new digest content identified.*

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 12, pp. 135–146 22 March 2024

<https://iris.who.int/bitstream/handle/10665/376320/WER9912-eng-fre.pdf>

:: Recommended composition of influenza virus vaccines for use in the 2024–2025 northern hemisphere influenza season

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

29 March 2024

[Policy brief – Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis...](#)

29 March 2024

[Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection](#)

26 March 2024

[Genomics costing tool](#)

Overview

The first edition of the genomics costing tool (GCT) facilitates budgeting and resource mobilization for infrastructure, workforce, biosafety and quality assurance associated with SARS-CoV-2 genomic surveillance. This tool will be useful to country, regional and global policymakers, health administrators and economists, laboratory directors, quality managers, donor institutions and other stakeholders engaged in genomic surveillance for priority pathogens. The GCT is a Microsoft Excel-based tool which is accompanied by a user manual to guide its users.

:: Download the genomics costing tool [here](#)

:: Download the genomics costing tool user manual [here](#)

26 March 2024

[Regional action framework on communication for health: a vision for using communication to improve public...](#)

25 March 2024

[Benefits and risks of using artificial intelligence for pharmaceutical development and delivery](#)

Overview

WHO recognizes that artificial intelligence (AI) holds great promise for pharmaceutical development and delivery. However, AI also presents risks and ethical challenges that must be addressed if societies, health systems and individuals are to fully reap its benefits. This discussion paper examines the expanding application of AI to each step of development and deployment of medicines and vaccines. AI is already used in most steps of pharmaceutical development, and, in the future, it is likely that nearly all pharmaceutical products that come to market will have been “touched” by AI

at some point in their development, approval or marketing. Although these uses of AI may have a commercial benefit, it is imperative that use of AI also has public health benefit and appropriate governance

PDF: <https://iris.who.int/bitstream/handle/10665/375871/9789240088108-eng.pdf?sequence=1>

.....
.....

USA – HHS, FDA, CDC

HHS

News

[Joint Statement by Secretary Of Health and Human Services Xavier Becerra and Secretary of State Antony J. Blinken](#) [Pandemic Accord]

March 29, 2024

Under President Biden’s leadership, the United States has coordinated global efforts to end the acute phase of the COVID-19 pandemic and ensure the international community is better prepared to respond to the next pandemic.

Consistent with our longstanding commitment to global health and security, the United States has worked closely with allies and partners to help safeguard the world from biological threats, including infectious disease outbreaks. Our first responsibility is protecting the lives and livelihoods of the American people and the security of our country. We cannot do that effectively unless we are preventing, detecting, and stopping outbreaks before they reach our shores.

That’s why we are working constructively with the global community to negotiate an international instrument on pandemic prevention, preparedness, and response. The proposals the United States has advanced would help secure the health and wellbeing of the American people, as well as people around the world, while also protecting against social and economic upheaval from future pandemics as the world experienced from COVID-19.

The United States’ commitment to protecting lives around the world is steadfast and unwavering. PEPFAR, one of our nation’s most profound global investments, has saved 25 million lives. During the West African outbreak of Ebola that started in 2014, the United States supported the accelerated development of critical vaccines, therapeutics, and diagnostics and, since that outbreak ended in 2016, we have continued to ensure that African nations have had timely access to medicines during every Ebola outbreak. We are improving global coordination, investing in countermeasures, and taking on emergent challenges like Antimicrobial Resistance.

The proposals we have advanced underscore our commitment to work together, with the international community, to prevent health crises like COVID-19 from happening again. For additional information, please visit: <https://www.hhs.gov/about/news/2024/03/29/joint-update-department-state-department-health-human-services-negotiations-toward-pandemic-accord.html>

[Factsheet: Joint Update by the Department of State and the Department of Health and Human Services on Negotiations Toward a Pandemic Accord](#)

March 29, 2024 News Release

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)

CDC/ACIP [U.S.] [to 30 Mar 2024]
<http://www.cdc.gov/media/index.html>
Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
June 26-28

MMWR Weekly
<https://www.cdc.gov/mmwr/index2023.html>
March 28, 2024 / No. 12
[PDF of this issue](#)

- [Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020](#)
- [Ceftriaxone-Resistant Gonorrhoea — China, 2022](#)
- [Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels — United States, May 2022–April 2023](#)
- [Tuberculosis — United States, 2023](#)
- [Interim Effectiveness of Updated 2023–2024 \(Monovalent XBB.1.5\) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]
<https://www.ema.europa.eu/en/news>
News & Press Releases

[EU recommendations for 2024/2025 seasonal flu vaccine composition](#)

EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
26 March 2024

European Centre for Disease Prevention and Control
<https://www.ecdc.europa.eu/en>
News/Updates/Reports/Publications [Selected]
Scientific and technical publications

[Avian influenza overview December 2023–March 2024](#)

26 Mar 2024

Between 2 December 2023 and 15 March 2024, highly pathogenic avian influenza (HPAI) A(H5) outbreaks were reported in domestic (227) and wild (414) birds across 26 countries in Europe.

.....
.....

Africa CDC [to 30 Mar 2024]
<https://africacdc.org/>

Press Releases, Statements [Selected]
No new digest content identified.



China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 30 Mar 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 30 Mar 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-03-29 / No. 13 ENVIRONMENTAL HEALTH ISSUE

[PDF of this issue](#)



Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)



Organization Announcements

Paul G. Allen Frontiers Group [to 30 Mar 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 30 Mar 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 30 Mar 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 30 Mar 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 30 Mar 2024]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 30 Mar 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 30 Mar 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 30 Mar 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 30 Mar 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

24 March 2024

[**World TB Day 2024: Funding innovative research to end TB**](#)

Emory Vaccine Center [to 30 Mar 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

Emory Max Cooper Prize in Immunology

Open to national and international candidates across the spectrum of immunology. The inaugural prize will be awarded in the fall of 2024.

European Vaccine Initiative [to 30 Mar 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 30 Mar 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

Readability of vaccine information

Added March 24, 2024

Funding sources: This research is reported to be supported by the Japan Society for the Promotion of Science KAKENHI.

What is this? In this systematic review, the authors searched for studies that examined the readability of vaccine information in both online and offline materials. They did not restrict their searches by date, type, or language of publication. The authors searched in September 2020 and identified 12 studies from Australia (1), Canada (2), Japan (2), and the USA (7).

What was found: The readability of vaccine information was found to be higher than an 8th level of reading. Very little information was presented at or below the recommended 5th to 6th level of reading. Anti-vaccination messages were substantially easier to read than pro-vaccine messages. Implications: The authors of this review stated that difficulty reading vaccine information may influence vaccine hesitancy. They recommended that healthcare professionals use guidelines and tools to create easy-to-read vaccine information.

Allocation of intensive care beds and ventilator treatment during pandemics

Added March 23, 2024

What was found: Consistent ethical, legal, and practical considerations that adhere to local service policies should be addressed at every step of the triage process. Transparent, objective parameters should be used to determine a patient's risk profile and the need for immediate care. No decision should be based on a single parameter or an undesirable feature. A list of possible criteria for rationing could help to avoid prejudice in decision-making. Patients with a good prognosis had the highest priority for ventilator and ICU access.

No consensus was found to aid decision-making for contentious ethical issues, such as possible age discrimination. Triage in under-resourced situations can only aim for practicality.

Fondation Merieux [to 30 Mar 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 30 Mar 2024]

<https://www.gavi.org/>

News Releases

25 March 2024

[World Bank and partners to build on support for improved health and nutrition in Lao PDR](#)

GE2P2 Global Foundation [to 30 Mar 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 07 March 2024 – Issue 14](#)

GHIT Fund [to 30 Mar 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 30 Mar 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 30 Mar 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 30 Mar 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 30 Mar 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 30 Mar 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 30 Mar 2024]

<https://www.iavi.org/>

News, Features

Press Releases

[IAVI and WomenLift Health announce partnership to promote women's leadership in global health](#)

February 27, 2024

Memorandum of understanding targets gender equity, mentorship, and training to expand the power and influence of talented women in science.

INSERM [to 30 Mar 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 30 Mar 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 30 Mar 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 30 Mar 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 30 Mar 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 28.03.2024

Inauguration in Brazil of the Institut Pasteur de São Paulo, member of the Pasteur Network Network

On March 27, 2024, the Institut Pasteur de São Paulo was inaugurated by French President, Emmanuel Macron. As a member...

ISC / International Science Council [to 30 Mar 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Press releases

Bridging the Gap: New Report Highlights Global Strategies for Accelerating AI in Science and Research

While advancements in AI have huge implications for national R&D systems, very little is known about how governments plan to accelerate the uptake of AI by science and research institutions. In "Preparing National Research Ecosystems for AI: Strategies and Progress in 2024", the International Science Council's Centre for Science Futures addresses this knowledge gap by presenting a review of the existing literature on this topic, as well as a series of country case studies.

28.03.2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 30 Mar 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

March 22, 2024

Low Immunization Coverage Leads to Global Increase in Measles Cases

IVI [to 30 Mar 2024]

<http://www.ivi.int/>

IVI News & Announcements

Vaccines for Africa, made in Africa, through end-to-end vaccine research and development projects: a side event co-hosted by IVI, Kenya, Africa CDC

Mar 20, 2024

A call to action for sustainable vaccine manufacturing in Africa was at the heart of our discussions during a side event at the margins of the 37th African Union Summit on February 18, 2024. IVI, the Government of Kenya, and Africa CDC co-hosted this key gathering of heads of state and other government officials, public health experts, pharmaceutical industry leaders, and international partners to advocate for end-to-end vaccine research and development projects as the foundation of an integrated African vaccine ecosystem...

Johns Hopkins Center for Health Security [to 30 Mar 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 30 Mar 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

South Sudan

[Urgent vaccination campaign needed to halt deadly measles outbreak in Western Equatoria s...](#)

Press Release 26 Mar 2024

Conflict in Sudan

[Displaced by war, people in eastern Sudan urgently need food, water and shelter](#)

Project Update 26 Mar 2024

Yemen

[The upsurge in measles cases shows no sign of abating](#)

Voices from the Field 26 Mar 2024

National Academy of Medicine - USA [to 30 Mar 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academy of Sciences - USA [to 30 Mar 2024]

<https://www.nationalacademies.org/newsroom?>

News

[Action Needed to Improve U.S. Smallpox Readiness and Diagnostics, Vaccines, and Therapeutics, Says New Report](#)

News Release | March 26, 2024

WASHINGTON — A [new report](#) from the National Academies of Sciences, Engineering, and Medicine says that action is needed to enhance U.S. readiness for smallpox and related diseases, as well as to improve diagnostics, vaccines, and therapeutics that could be used in case of an outbreak. The COVID-19 pandemic revealed weaknesses in the ability of U.S. public health and health care systems to adapt and respond to an unfamiliar pathogen, as did challenges during the recent mpox outbreak to rapidly making diagnostics, vaccines, and therapeutics available at scale.

National Vaccine Program Office - U.S. HHS [to 30 Mar 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

June 13-14, 2024

NIH [to 30 Mar 2024]

<http://www.nih.gov/>

New Releases

[NIH selects Dr. Kathleen Neuzil as director of the Fogarty International Center and NIH associate director for international research](#)

March 28, 2024 — Dr. Neuzil, the first woman to hold the permanent FIC directorship, will begin in early May.

PATH [to 30 Mar 2024]

<https://www.path.org/media-center/>

Newsroom

[PATH concerned about funding cuts to global health security in US budget deal](#)

The following is a statement regarding the FY24 budget signed by President Biden.

Sabin Vaccine Institute [to 30 Mar 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 30 Mar 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press release

[With a modest increase in investment UNAIDS can get 35 countries over the line to end their AIDS pandemics by 2025](#)

UNAIDS needs to increase funding to just 1% of the US\$ 20 billion HIV resources to effectively support countries in their goal of ending AIDS by 2030

GENEVA, 28 March 2024—UNAIDS is urging donors for a modest increase in funding to ensure that 35 countries can end their AIDS pandemics by 2025, five years ahead of the 2030 target. Current funding for UNAIDS is at US\$ 160 million, less than 50% than the resources available in 2015. For maximum impact UNAIDS estimates it will need US\$ 210 million annually which represents less than 0.02% of total health spending in low- and middle-income countries...

27 March 2024

[Haiti's crisis exacerbates vulnerability of people living with and affected by HIV. UNAIDS committed to continuing to provide support to people in need.](#)

UNICEF [to 30 Mar 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 26 March 2024

[9 years into the conflict in Yemen, millions of children are malnourished and stunted](#)

SANA'A/NEW YORK 26 March 2024 – Nine years into the conflict in Yemen, almost 10 million children remain in urgent need of humanitarian assistance. While the reduction in active conflict since April 2022 has led to a decrease in civilian casualties and distress across communities, the situation remains fragile without a sustainable political...

Visit the page

News note 26 March 2024

[Gaza's Children: Trapped in a Cycle of Suffering](#)

GAZA, 26 March 2024 – “Today I would like to speak about two major issues that people here in Gaza say are central to their survival. The safety of those in Rafah, and aid delivery. “Today Rafah is unrecognizable because of the congestion, and tents on street corners and sandy plots. People sleep in the streets, in public buildings, in any other...

Press release 26 March 2024

[Armed violence deepening malnutrition crisis for children in Haiti](#)

PORT AU PRINCE/NEW YORK, 26 March 2024 - The alarming surge in armed violence in areas of Haiti is creating heightened risk of furthering a malnutrition crisis in the country, UNICEF warned today. The recent findings from the Integrated Food Security Phase Classification (IPC) analysis indicate an alarming 19 per cent increase in the number of...

Unitaid [to 30 Mar 2024]

<https://unitaid.org/>

Featured News

28 March 2024

[“Liquid medical oxygen can level the playing field”](#)

Vaccine Equity Cooperative [nee Initiative] [to 30 Mar 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 30 Mar 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 30 Mar 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 30 Mar 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[March 2024: Vaccines and Infectious Diseases in the News](#)

Published on Mar 19, 2024

Wellcome Trust [to 30 Mar 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 30 Mar 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 30 Mar 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 30 Mar 2024]

<https://www.wfpha.org/>

Blog

[GPHW2024: Lecture on Protecting Health Workforce: Recommendations to Develop & Implement Dedicated Vaccination Programs](#)

Mar 28, 2024

GPHW2024: Lecture on Protecting Health Workforce: Recommendations to Develop & Implement Dedicated Vaccination Programs
Theme: Enhancing and Democratizing Governance in Global Health
Date and Time: 9th April 2024 | 14:00-14:20 (CET) Event...

[World Medical Association \[WMA\]](#) [to 30 Mar 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 30 Mar 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 30 Mar 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

[ARM's Statement on the EU's Health Technology Assessment Guideline](#)

March 25, 2024 Brussels, BE

The EU Health Technology Assessment (HTA) Coordination Group's 'Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons' is discouraging news for rare disease patients and the Advanced Therapy Medicinal Products (ATMP) sector...

BIO [to 30 Mar 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 30 Mar 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 30 Mar 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 30 Mar 2024]

<https://ifpma.org/>

News

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 30 Mar 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 30 Mar 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

[Beyfortus approved in Japan for the prevention of RSV disease in infants](#)

27 March 2024

Bharat Biotech

Press Releases

Mar 24: **[MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India](#)**

:: Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine.

:: Bharat Biotech International Limited in collaboration with Biofabri have started a series of clinical trials to evaluate the safety, immunogenicity and efficacy of MTBVAC in India.

:: MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns, and for the prevention of TB disease in adults and adolescents, for whom there is currently no effective vaccine.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

Press Releases

March 27, 2024

[IR Insights: Recapping our Fifth Annual Vaccines Day](#)

March 27, 2024

[Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials](#)

- Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints
- Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV
- Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development
- Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024
- Announces development and commercialization funding agreement with Blackstone Life Sciences for up to \$750 million to advance flu program

March 26, 2024

[Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine](#)

Nanogen

[News](#) - No new digest announcements identified

Novartis

[News](#) - No new digest announcements identified.

Novavax

[Press Releases](#) - No new digest announcements identified.

Pfizer

[Recent Press Releases](#) - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified

Serum Institute of India

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified [English translation function not operating]

Sinovac

[Press Releases](#)

[SINOVAC Begins Clinical Trial for Reassortant Hexavalent Rotavirus Vaccine](#)

Beijing, China – March 27, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has initiated Phase I clinical trial of its Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell), and 20 people have finished enrollment on the first day.

This vaccine has been approved for clinical trial in January 2024. The study has two parts: an open-label, single-arm group involving adults and children; and a randomized, double-blinded, placebo-controlled group of infants, to evaluate the safety and tolerance in participants, and immunogenicity in infants of this vaccine...

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#)

March 26, 2024

[Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate](#)

Vector State Research Centre of Virology and Biotechnology

[Home](#) - Website not responding [404 error]

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 3: E195-273 Mar 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Psychiatric Inpatient Environmental Architecture

Inpatient psychiatric units designed to reduce patients' risk of harm to self or others can compromise patients' comfort. Some environmental modifications prioritize safety by limiting patients' access to personal items. This set of clinical phenomena is not ethically neutral and should prompt us to carefully consider when and how patients' experiences of their care environments undermine therapeutic goals of their hospitalizations. This theme issue investigates which criteria we should use to assess and evaluate patients' risk of harm to self or others and which values we should rely upon to guide which iatrogenic harm risks we accept as products or byproducts of clinical and organizational environmental designs.

[Reviewed earlier]

American Journal of Human Genetics

Mar 07, 2024 Volume 111 Issue 3 p403-620

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

In Our DNA SC, a program developed to ensure that all individuals in South Carolina have access to genomic screening, recently reached an interim milestone of 20,000 participants. Over 14 months, 20,478 participants enrolled, and 13,643 samples were collected through clinical appointments, 108 community events, or at-home sample collection. A total of 1.3% of participants were found to have a pathogenic or likely pathogenic variant for a CDC Tier 1 condition; 77.4% of those agreed to genetic counseling and 80.2% completed counseling.

American Journal of Infection Control

March 2024 Volume 52 Issue 3 p261-380

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

March 2024 Volume 66 Issue 3 p389-572

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

March 2024 114(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 3 (Mar 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-3.xml>

Perspective Open access

[Building Research Capacity in Low- and Middle-Income Countries and Pandemic Preparedness: Lessons Learned and Future Directions](#)

Peter H. Kilmarx, et al.

Volume/Issue: [Volume 110: Issue 3](#)

Article Category: Perspective

DOI: <https://doi.org/10.4269/ajtmh.23-0675>

[Building Environmental and Sociological Predictive Intelligence to Understand the Seasonal Threat of SARS-CoV-2 in Human Populations](#)

Moiz Usmani, et al.

Volume/Issue: [Volume 110: Issue 3](#)

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.23-0077>

[The Drivers of Low Vaccination Utilization in Niger](#)

Bernard Seytre, et al.

Volume/Issue: [Volume 110: Issue 3](#)

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.23-0708>

Annals of Internal Medicine

March 2024 Volume 177, Issue 3

<https://www.acpjournals.org/toc/aim/current>

[New issue; No digest content identified]

Artificial Intelligence – An International Journal

Volume 328 March 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/328/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 30 Mar 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 30 Mar 2024)

[Is the national health insurance scheme a pathway to sustained access to medicines in Nigeria?](#)

The debate surrounding access to medicines in Nigeria has become increasingly necessary due to the high cost of essential medicine drugs and the prevalence of counterfeit medicines in the country. The Nigerian...

Authors: Nkolika Uguru, Udochukwu Ogu, Chibuzo Uguru and Ogochukwu Ibe

Citation: BMC Health Services Research 2024 24:403

Content type: Research Published on: 29 March 2024

[Acceptance and expectations of healthcare workers and community during the COVID-19 vaccine rollout in Bhavnagar city, western India: a qualitative exploration](#)

COVID-19 vaccine was launched in India on January 16, 2021. There is a paucity of robust evidence from qualitative studies on the acceptability and expectations of potential recipients from the COVID-19 vaccin...

Authors: Mohit N. Makwana, Hiren J. Shekhda and Mihir P. Rupani

Citation: BMC Health Services Research 2024 24:386

Content type: Research Published on: 27 March 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 30 Mar 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 30 Mar 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 30 Mar 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 30 Mar 2024)

[Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines](#)

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections globally, with most RSV-related deaths occurring in infants < 6 months of age. The highest burden of RSV is in low-and...

Authors: Rupali J. Limaye, Prachi Singh, Berhaun Fesshaye and Ruth A. Karron

Citation: BMC Pregnancy and Childbirth 2024 24:221

Content type: Research Published on: 27 March 2024

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 30 Mar 2024)

[Influenza vaccine coverage and factors associated with non-vaccination among caregiving and care-receiving adults in the Canadian Longitudinal Study on Aging \(CLSA\)](#)

Influenza vaccination is recommended for those at increased risk of influenza complications and their household contacts to help reduce influenza exposure. Adults who require care often experience health issue...

Authors: Katie Gravagna, Christina Wolfson and Nicole E. Basta

Citation: BMC Public Health 2024 24:924

Content type: Research Published on: 29 March 2024

Neighborhood-level factors associated with COVID-19 vaccination rates: a case study in Chicago

Chicago's deeply-rooted racial and socioeconomic residential segregation is a pattern mirrored in other major cities, making it a prototype for studying the uptake of public health interventions across the US....

Authors: Grace Keegan, Mengqi Zhu, Maria Paz, Hyojung Kang, Ajanta Patel and Arshiya A. Baig

Citation: BMC Public Health 2024 24:889

Content type: Research Published on: 25 March 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 30 Mar 2024)

Determinants of COVID-19 vaccine uptake: evidence from a vulnerable global South setting

Studies are paying increasing attention to complex social determinants in explaining the variation in the rates COVID-19 vaccine uptake. This study examines the influence of various individual, contextual, and...

Authors: John Oti Amoah, Susanna Aba Abraham, Charles Atanga Adongo, Deogratias Kaheeru Sekimpi, David Cudjoe Adukpo, Dorcas Obiri-Yeboah and David Teye Doku

Citation: BMC Research Notes 2024 17:94

Content type: Research Note Published on: 29 March 2024

BMJ Evidence-Based Medicine

April 2024 - Volume 29 - 2

<https://ebm.bmj.com/content/29/2>

Analysis

Decision architecture randomisation: extremely efficient clinical trials that preserve clinician and patient choice? (21 July, 2023)

James Flory, Jessica S Ancker, Scott Yung Ho Kim, Gilad Kuperman, Andrew Vickers

Original research

Towards transparency: adoption of WHO best practices in clinical trial registration and reporting among top medical research funders in the USA (6 November, 2023)

Elise Gamertsfelder, Netzahualpilli Delgado Figueroa, Sarai Kestra, Alan Rossi Silva, Ronak Borana, Maximilian Siebert, Till Bruckner

BMJ Global Health

March 2024 - Volume 9 - 3

<https://gh.bmj.com/content/9/3>

[Reviewed earlier]

Bulletin of the Atomic Scientists

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(3); 2024 Mar 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/456622/>

[Reviewed earlier]

Cell

Feb 29, 2024 Volume 187 Issue 5 p1017-1314

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Subcutaneous Biologics: Clinical Pharmacology and Drug Development

[Reviewed earlier]

Clinical Therapeutics

February 2024 Volume 46 Issue 2 p85-184

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 1, February 2024

<https://journals.sagepub.com/toc/ctja/21/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 30 Mar 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 1 / February 2024

<https://www.liebertpub.com/toc/crispr/7/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 30 Mar 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

Access to Essential Medicines for Global Health and the Human Right to Health

[Reviewed earlier]

Development in Practice

Volume 34, Issue 1, 2024

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 2 April 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/2>

[New issue; No digest content identified]

EMBO Reports

Volume 25 Issue 3 12 March 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Indigenous data sovereignty :: Returning clinically relevant results

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 1, February 2024

<https://academic.oup.com/eurpub/issue/34/1>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2023 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 3 March 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/3>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 30 Mar 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 30 Mar 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 30 Mar 2024]

[Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models](#)

Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers' practices...

Authors: Adrián Alonso Ruiz, Anna Bezruki, Erika Shinabargar, Kaitlin Large, Marcela Vieira, Iulia Slovenski, Yiqi Liu, Surabhi Agarwal, Anna Becker and Suerie Moon

Citation: Globalization and Health 2024 20:25

Content type: Research Published on: 26 March 2024

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 2, March 2024

<https://academic.oup.com/heapol/issue/39/2>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 30 Mar 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 5-6 / March 2024

<https://www.liebertpub.com/toc/hum/35/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Mar 12, 2024 Volume 57 Issue 3 p401-612

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 30 Mar 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 30 Mar 2024]

[No new digest content identified]

International Health

Volume 16, Issue 2, March 2024

<https://academic.oup.com/inthealth/issue/16/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

March 26, 2024, Vol 331, No. 12, Pages 993-1070

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines](#)

Niklas Worm Andersson, MD; Emilia Myrup Thiesson, MSc; Anders Hviid, DrMedSci

free access

JAMA. 2024;331(12):1057-1059. doi:10.1001/jama.2024.1036

This study examines the association between XBB.1.5-containing vaccines administered as a fifth COVID-19 vaccine dose and the risk of 28 adverse events.

Viewpoint

[Misinformation and the Vaccine Adverse Event Reporting System](#)

Kathleen Hall Jamieson, PhD; Kevin B. Johnson, MD, MS; Anne R. Cappola, MD, ScM

JAMA. 2024;331(12):1005-1006. doi:10.1001/jama.2024.1757

This Viewpoint posits that to improve public understanding of the system, the Vaccine Adverse Event Reporting System (VAERS) could use a more accurate name, well-defined guidance about the reporting system's nature and use, and comprehensible information about an event's verification status.

Editorial

[Postmarketing Vaccine Safety Assessments- Important Work in Progress](#)

Kathryn M. Edwards, MD; Marie R. Griffin, MD, MPH

After the initial randomized clinical trials and emergency use authorization of the COVID-19 vaccines by the US Food and Drug Administration (FDA) during the COVID-19 pandemic, the US Centers for Disease Control and Prevention (CDC) and the FDA undertook extensive postmarketing vaccine safety surveillance activities in the US, with close monitoring by an independent safety committee.¹ Analysis of surveillance data identified several important adverse events associated with receipt of the COVID-19 vaccines.

JAMA Health Forum

March 2024, Vol 5, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

March 2024, Vol 178, No. 3, Pages 211-322

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

March 2024 - Volume 22 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

March 2024 Volume 74 Issue 3 p395-628

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 167 March 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 2 Pages: 773-1592 March 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

March 2024 - Volume 50 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 266 March 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2024 - Volume 30 - Issue 2

<https://onlinelibrary.wiley.com/toc/10991328/current>

Editorial

[Equitable Access to RSV Prevention: Challenges and Opportunities With Nirsevimab's Rollout](#)

Yang, Y. Tony; Schaffer DeRoo, Sarah

Journal of Public Health Management and Practice. 30(2):153-154, March/April 2024.

Research Reports

[The Relationship of Vaccine Uptake and COVID-19 Infections Among Nursing Home Staff and Residents in Missouri: A Measure of Risk by Community Mobility](#)

Scroggins, Stephen; Little, Germysa; Okala, Odiraa; More

Journal of Public Health Management and Practice. 30(2):176-182, March/April 2024.

Journal of Public Health Policy

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[Reviewed earlier]

Journal of the Royal Society – Interface

March 2024 Volume 21 Issue 212

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 2, March 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Mar 30, 2024 Volume 403 Number 10433 p1205-1308

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data](#)

Xin Wang, et al/ for the RESCEU investigators

Open Access

Viewpoint

[The Lancet and colonialism: past, present, and future](#)

Mishal S Khan, et al.

Summary

The historical and contemporary alignment of medical and health journals with colonial practices needs elucidation. Colonialism, which sought to exploit colonised people and places, was justified by the prejudice that colonised people's ways of knowing and being are inferior to those of the colonisers. Institutions for knowledge production and dissemination, including academic journals, were therefore central to sustaining colonialism and its legacies today. This invited Viewpoint focuses on The Lancet, following its 200th anniversary, and is especially important given the extent of The Lancet's global influence. We illuminate links between The Lancet and colonialism, with examples from the past and present, showing how the journal legitimised and continues to promote specific types of knowers, knowledge, perspectives, and interpretations in health and medicine. The Lancet's role in colonialism is not unique; other institutions and publications across the British empire cooperated with empire-building through colonisation. We therefore propose investigations and raise questions to encourage broader contestation on the practices, audience, positionality, and ownership of journals claiming leadership in global knowledge production.

The Lancet Child & Adolescent Health

Mar 2024 Volume 8 Number 3 p175-244, e2-e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Mar 2024 Volume 6 Number 3 e145-e229

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Mar 2024 Volume 12 Number 3 e341-e529

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Mar 2024 Volume 24 Number 3 p217-328, e137-e206

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Mar 2024 Volume 9 Number 3 e147-e206

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Mar 2024 Volume 12 Number 3 p181-254, e7-e12

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 3 March 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-3>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 2, February 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 1 Pages: 1-269 March 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Mar 06, 2024 Volume 32 Issue 3 p563-856

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 627 Issue 8005, 28 March 2024
<https://www.nature.com/nature/volumes/627/issues/8005>
[New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 3, March 2024
<https://www.nature.com/nbt/volumes/42/issues/3>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 30 Mar 2024)
[No new digest content identified]

Nature Genetics

Volume 56 Issue 3, March 2024
<https://www.nature.com/ng/volumes/56/issues/3>
[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 3, March 2024
<https://www.nature.com/nathumbehav/volumes/8/issues/3>
Comment 29 Jan 2024

[Five creative ways to promote reproducible science](#)

The importance of reproducible scientific practices is widely acknowledged. However, limited resources and lack of external incentives have hindered their adoption. Here, we explore ways to promote reproducible science in practice.

Josefina Weinerova, Rotem Botvinik-Nezer, Roni Tibon

Nature Medicine

Volume 30 Issue 3, March 2024
<https://www.nature.com/nm/volumes/30/issues/3>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 3, March 2024
<https://www.nature.com/nrd/volumes/23/issues/3>
[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 3, March 2024
<https://www.nature.com/nrg/volumes/25/issues/3>
[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 3, March 2024

<https://www.nature.com/nri/volumes/24/issues/3>

[Reviewed earlier]

New England Journal of Medicine

March 21/28 2024 Vol. 390 No. 12

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 30 Mar 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 3 March 2024

<https://publications.aap.org/pediatrics/issue/153/3>

[Reviewed earlier]

Pharmacoeconomics

Volume 42, Issue 3 March 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 30 Mar 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 30 Mar 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 30 Mar 2024)

[HIV stigma and other barriers to COVID-19 vaccine uptake among Georgian people living with HIV/AIDS: A mixed-methods study](#)

Tamar Zurashvili, Tsira Chakhaia, Elizabeth J. King, Jack DeHovitz, Mamuka Djibuti

Research Article | published 28 Mar 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003069>

[A qualitative inquiry on drivers of COVID-19 vaccine hesitancy among adults in Kenya](#)

Stacey Orangi, Daniel Mbuthia, Elwyn Chondo, Carol Ngunu, Evelyn Kabia, John Ojal, Edwine Barasa
Research Article | published 28 Mar 2024 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0002986>

[COVID-19 vaccine uptake and barriers among Indigenous language speakers in Mexico: Results from a nationally representative survey](#)

Lucía Abascal Miguel, Cesar A. Mendez-Lizarraga, Elizabeth M. Rojo, Jaime Sepúlveda
Research Article | published 28 Mar 2024 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0002921>

PLoS Medicine

<http://www.plosmedicine.org/>
(Accessed 30 Mar 2024)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>
(Accessed 30 Mar 2024)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>
[Accessed 30 Mar 2024]

[Post-campaign coverage evaluation of a measles and rubella supplementary immunization activity in five districts in India, 2019–2020](#)

Jeromie Wesley Vivian Thangaraj, Christine Prospero, Muthusamy Santhosh Kumar, Alvira Z. Hasan, V. Saravana Kumar, Amy K. Winter, Avi Kumar Bansal, Sanjay L. Chauhan, Gagandeep Singh Grover, Arun Kumar Jain, Ragini N. Kulkarni, Santanu Kumar Sharma, Biju Soman, Itta K. Chaaithanya, Sanchit Kharwal, Sunil K. Mishra, Neha R. Salvi, Nilanju P. Sarmah, Sandeep Sharma, Adarsh Varghese, R. Sabarinathan, Augustine Duraiswamy, D. Sudha Rani, K. Kanagasabai, Abhishek Lachyan, Poonam Gawali, Mitali Kapoor, Saurabh Kumar Chonker, Lucky Sangal, Sanjay M. Mehendale, Gajanan N. Sapkal, Nivedita Gupta, Kyla Hayford, William J. Moss, Manoj V. Murherkar
Research Article | published 29 Mar 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0297385>

[Progress and challenges in achieving tuberculosis elimination in India by 2025: A systematic review and meta-analysis](#)

Abhishek Padhi, Ashwini Agarwal, Mayuri Bhise, Anil Chaudhary, Krupal Joshi, C. D. S. Katoch
Registered Report Protocol | published 27 Mar 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0301060>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 30 Mar 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

March 26, 2024 vol. 121 no. 13

<https://www.pnas.org/toc/pnas/121/13>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 2, February 2024

<https://academic.oup.com/pnasnexus/issue/3/2>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 1 - February 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 180 March 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

27 March 2024 Volume 291 Issue 2019

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 228 Pages e1-e4, 1-206 (March 2024)

<https://www.sciencedirect.com/journal/public-health/vol/228/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 4, March 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 30 Mar 2024]

[Knowledge and perception of HPV vaccination among Lebanese mothers of children between nine and 17 years old](#)

The human papillomavirus (HPV), a prevalent sexually transmitted infection, is linked to a wide range of diseases, with cervical cancer being the most common and serious one. HPV vaccination is crucial for pre...

Authors: Nassif Elissa, Hadchity Charbel, Azzi Marly, Nader Ingrid, Saleh Nadine and Abdo Rachel

Citation: Reproductive Health 2024 21:40

Content type: Research Published on: 27 March 2024

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

1 Apr 2024

[Corrigendum Research priority-setting is an ethics exercise: lessons from the Global Forum on Bioethics in Research for the Region of the Americas](#)

Letter | English |

Risk Analysis

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 30 Mar 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6690| 29 Mar 2024

<https://www.science.org/toc/science/current>

Research Articles

[BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination](#)

BY Abebe Fromsa, et al.

29 Mar 2024

Bacillus Calmette-Guérin (BCG) is a routinely used vaccine for protecting children against Mycobacterium tuberculosis that comprises attenuated Mycobacterium bovis. BCG can also be used to protect livestock against M. bovis; however, its effectiveness .

Science and Engineering Ethics

Volume 30, Issue 2 April 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-2>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 740| 27 Mar 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 30 Mar 2024]

[No new digest content identified]

Social Science & Medicine

Volume 346 April 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C>

Review article Open access

[Health emergencies, science contrarianism and populism: A scoping review](#)

Marina Schenkel

Article 116691

Research article Open access

[Agency in urgency and uncertainty. Vaccines and vaccination in European media discourses](#)

Aleksandra Wagner, Paulina Polak, Tadeusz Józef Rudek, Maria Świątkiewicz-Mośny, ... Pia Vuolanto

Article 116725

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 30 Mar 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 16| Issue 739| 20 Mar 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 58 March–April 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 3 Pages: i-iv, 161-255 March 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 8 Pages 1855-2114 (19 March 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/8>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 30 Mar 2024]

[New issue; No digest content identified]

Value in Health

March 2024 Volume 27 Issue 3 p271-382

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 30 Mar 2024]

Selected Research

Research Article metrics

Revised

[Expanding options for HIV testing: A process evaluation of a community-led HIV self-testing intervention among men who have sex with men in Kenya](#)

[version 2; peer review: 1 approved, 1 approved with reservations]

Memory Melon, Bernadette Kombo, Mary Mugambi, Margaret Njiraini, Kennedy Olango, Manas Migot, Samuel Kuria, Martin Kyana, Peter Mwakazi, Japheth Kioko, Shem Kaosa, Maria Mensah, Matthew Thomann, Janet Musimbi, Helgar Musyoki, Parinita Bhattacharjee, Robert Lorway, Lisa Lazarus

Peer Reviewers Sandra Hsu Hnin Mon; Cedric Bien-Gund

Funder

Bill and Melinda Gates Foundation

LATEST VERSION PUBLISHED 25 Mar 2024

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 30 Mar 2024]

[Filter: All articles]

[A Health Economic Evaluation for Implementing an Extended Half-life Monoclonal Antibody for All Infants vs. Standard Care for Respiratory Syncytial Virus Prophylaxis in Canada](#)

Thomas Shin, Jason K.H. Lee, Alexia Kieffer, Michael Greenberg, Jianhong Wu

medRxiv 2024.03.28.24305020; doi: <https://doi.org/10.1101/2024.03.28.24305020>

[Strengthening access to and confidence in COVID-19 vaccines among equity-deserving populations across Canada: An exploratory qualitative study](#)

Kainat Bashir, Mariame O. Ouedraogo, Christoffer Dharma, Mercedes Sobers, Vajini Atukorale, Dane Mauer-Vakil, Anushka Ataullahjan, Shaza A. Fadel, Sara Allin

medRxiv 2024.03.27.24304984; doi: <https://doi.org/10.1101/2024.03.27.24304984>

There is a need to reflect on the COVID-19 vaccine distribution across Canada and the extent to which they considered equity-deserving populations. This paper examined and compared strategies implemented by six Canadian provinces to increase access and promote the uptake of COVID-19 vaccines among selected priority populations. We also explored the factors that impacted the implementation of these strategies.

[The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2](#)

Brooke E Nichols, Alexandra de Nooy, Naseem Cassim, Lucia Hans, Manuel Pedro da Silva, Kamy Chetty, Kyra H Grantz, Alvin X. Han, Andrew N Phillips, Lise Jamieson, Lesley E Scott, Wendy S Stevens

medRxiv 2024.03.27.24304888; doi: <https://doi.org/10.1101/2024.03.27.24304888>

[Values and preferences in COVID-19 public health guidelines: A systematic review](#)

Sarah Kirsh, Michael Ling, Tanvir Jassal, Tyler Pitre, Thomas Pigott, Dena Zeraatkar

medRxiv 2024.03.25.24304859; doi: <https://doi.org/10.1101/2024.03.25.24304859>

[Assessing yellow fever outbreak potential and implications for vaccine strategy](#)

Keith Fraser, Arran Hamlet, Kévin Jean, Daniel Garkauskas Ramos, Alessandro Romano, Jennifer Horton, Laurence Cibrelus, Neil Ferguson, Katy A.M. Gaythorpe
medRxiv 2023.12.19.23300139; doi: <https://doi.org/10.1101/2023.12.19.23300139> Revision

[Mathematical models of COVID-19 vaccination in high-income countries: A systematic review](#)

Eleanor Burch, Saher Aijaz Khan, Jack Stone, Asra Asgharzadeh, Joshua Dawe, Zoe Ward, Ellen Brooks-Pollock, Hannah Christensen
medRxiv 2024.03.24.24304676; doi: <https://doi.org/10.1101/2024.03.24.24304676>

[Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants](#)

Gebremedhin B. Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis, Ashleigh R. Tuite
medRxiv 2024.03.21.24304675; doi: <https://doi.org/10.1101/2024.03.21.24304675>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>
[Accessed 30 Mar 2024]
Selected Research
[No new digest content identified]

* * * *

[Think Tanks](#)

Brookings [to 30 Mar 2024]
<http://www.brookings.edu/>
Research
No new digest content identified.

Center for Global Development [to 30 Mar 2024]
<https://www.cgdev.org/>
All Research [Selected]
No new digest content identified.

Chatham House [to 30 Mar 2024]
<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 30 Mar 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 30 Mar 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 30 Mar 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 30 Mar 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 30 Mar 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 30 Mar 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 30 Mar 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 30 Mar 2024]

<https://www.urban.org/publications>

[**New Research Publications - Selected**](#)

Research Report

[**Advancing Vaccine Equity through Community-Based Organizations**](#)

March 28, 2024

The Centers for Disease Control and Prevention launched the Partnering for Vaccine Equity (P4VE) program in 2020 to address racial and ethnic disparities in adult immunization rates, particularly for COVID-19 and influenza. The P4VE program allocated \$156 million to over 500 national, state, and community-based organizations (CBOs) to improve equitable access to vaccination in underserved communities by promoting vaccine confidence and addressing barriers to vaccination opportunities.

The Urban Institute (Urban) is one of several national intermediary entities responsible for recruiting, overseeing, and providing technical assistance to CBOs participating in the P4VE program. This report describes the experiences of Urban's 28 CBO awardees and the technical support that the Urban team provided them to implement vaccine equity projects in the second year of the P4VE program...

World Economic Forum [to 30 Mar 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

[Online public consultation on the draft Key criteria for the ethical acceptability of controlled human infection studies during public health emergencies](#)

WHO 7 March 2024 *Call for consultation*

Deadline for submission: 7th April 2024 [11:59 on Sunday, Central European Time (GMT/UHC +1)]

Objective of the consultation

The goal of this online, open public consultation is to gather feedback from stakeholders on the draft/

Background

This consultation is part of the WHO Health Ethics and Governance Unit's commitment to promoting ethical research. The Unit produced Key Criteria for the Ethical Acceptability of COVID-19 Human Challenge Studies (2020) and broader WHO Guidance on the Ethical Conduct of Controlled Human Infection Studies (2021). Controlled human infection studies (CHIS) were conducted with COVID19 in the United Kingdom during the COVID-19 pandemic public health emergency.

It is likely that CHIS may be considered in future infectious disease public health emergencies. The draft document circulated in this consultation aims to provide general ethics guidance for CHIS during emergencies. Such guidance is intended to supplement existing mechanisms for ethical consideration and research ethics review of CHIS by highlighting issues that would be likely to be highly salient to CHIS during an emergency.

Future emergencies may be caused by different types of pathogens and the features of future emergencies may be difficult to predict. However, recent experience has demonstrated that certain ethical issues may be particularly relevant to CHIS in such settings and that prospective ethical guidance may be useful to inform the evaluation of such studies. While the current draft document focuses on CHIS during emergencies, the Health Ethics and Governance Unit also aims to produce complimentary guidance on CHIS with pathogens of pandemic potential as part of emergency preparedness.

[Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards](#)

21 CFR Part 50 [Docket No. FDA-2022-D-2997] **Comments due: 04/30/2024**

SUMMARY:

This draft guidance provides recommendations related to two provisions of the revised Federal Policy for the Protection of Human Subjects (the revised Common Rule) by the U.S. Department of Health and Human Services (HHS) and identical provisions in FDA’s proposed rule “Protection of Human Subjects and Institutional Review Boards.” FDA’s proposed rule, if finalized, would harmonize certain sections of FDA’s regulations on human subject protections and institutional review boards (IRBs), to the extent practicable and consistent with other statutory provisions, with the revised Common Rule, in accordance with the 21st Century Cures Act (Cures Act). The guidance addresses the provisions of the revised Common Rule that require informed consent to begin with key information about the research and to present information in a way that facilitates understanding and identical provisions in FDA’s proposed rule.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *

*

*

*

*